2,6-二甲基苯胺作为基因毒性杂质控制,它的每日最大摄入量是多少?(1.5μg/天做不到)
目前找到一个雷诺嗪缓释片在澳洲申报的资料中提到2,6-二甲基苯胺的每日最大摄入量范围是20.4μg/天~110μg/天,有没有哪位大神知道这两个值的来源及推导过程,求助。
原文如下:
The sponsor also commissioned two nonclinical risk assessments on DMA relative to potential exposure from ranolazine under the conditions of use. Both assessors referred to methodologies advocated in the ICH guideline.21 The updated guideline permits the use of compound-specific assessments (compared with. TTC-based acceptable intake of 1.5 μg/day) when sufficient carcinogenicity data exists, such that a compound-specific acceptable intake can be extrapolated from measures of carcinogenic potency. Information on the carcinogenicity of DMA is available from a 2 year dietary study in rats (NTP, 1990) and is the only source of data on carcinogenic potency. The first nonclinical assessor referred to a follow-up report to the NTP report where carcinogenic potential (TD50) was set at 20.4 mg/kg. By linear extrapolation the acceptable lifetime daily intake was calculated as 0.41 μg/kg/day (24.5 μg/day for 60 kg adult or 20.4 μg/day for 50 kg adult). The amount of DMA detected in 750 mg ranolazine tablets after 24 months storage (1.6 μg/tablet or 3.2 μg/day based on average batch values outlined above in Table 7) were at least 6.4 fold lower than the extrapolated acceptable lifetime daily intake of 20.4 μg/day (for 50 kg adult at the MRHD). The assessor indicated that this was an acceptable safety factor but recommended that the shelf life of Ranexa be no more than 24 months to ensure ranolazine degradation was minimal. The second nonclinical assessor evaluated risk assessments conducted by other regulatory bodies where acceptable daily levels of DMA ranged between 20.4 μg/day to 110 μg/day (for 50 kg adult). The most conservative approach gave acceptable daily levels of 29 μg/day (20.4 μg/day for 50 kg adult) and was the same as that outlined by the first……
根据ICH M7的要求计算来的 PDE=TD50/50000*50,也就是20.4mg/kg除以50000=0.41ug/kg/天,再乘以体重50Kg就得到PDE 20.4ug/天,20.4再除以你的最大日计量就得到你的限度。如果还不明白加个微信跟你讲一下。再把ICH M7的中文版发给你。
当前为付费需求,赏金分配方式:一人独享赏金。
任务主在众多备选稿件中选择最满意的稿件,支付赏金。
任务主把所发需求的悬赏金托管到药智网指定账户,以激发众多药智客的参与热情,保障任务主尽快征集到满意稿件;
同时,赏金托管也是为了保障参与挑战的药智客的正当权益。
点击“发布需求”按钮,按照流程引导,将需求详情、具体要求描述清楚,发布到药智网的药智汇平台。
为征集到满意稿件,任务主须做好“赏金预算”,并将赏金托管到药智网指定账户,打消药智客的顾虑,激励药智客积极参与需求挑战。
任务主托管赏金后,所发布的需求显示“赏金已托管”字样。只有托管了悬赏金的需求,能够鼓舞众多的药智客参与,获取到满意的稿件!
任务主在众多参与者提交的稿件中,选择符合任务主需求的稿件。再通过互动,选择任务主最满意的稿件,并确定其为中标稿件。
中标稿件提交任务主验收。任务主在验收/验证期内,完成验收/验证工作。对合格稿件,通知药智网支付佣金。
双方可以针对本次交易各自的表现进行评价,评价结果将影响各自的信用度和能力值。
关于我们 产品与服务 资质荣誉 联系我们 智库专家 诚聘英才 帮助中心 网站地图 用户体验提升计划
互联网增值电信业务许可证编号:渝B2-20120028 | 渝ICP备10200070号-3 互联网药品信息服务资格证:(渝)-经营性-2021-0017
康洲大数据 Copyright © 2009-2024 药智网 YAOZH.COM All Rights Reserved. 法律顾问:重庆中世律师事务所 王凡律师
客户服务热线:400-678-0778 E-mail:service@yaozh.com
本网站用字经北京北大方正电子有限公司授权许可
投诉热线: (023) 6262 8397
邮箱: tousu@yaozh.com
渝公网安备 50010802001068号
投诉热线: (023) 6262 8397
邮箱: tousu@yaozh.com
QQ: 236960938
药智网公众号
药智数据试用申请